Your browser doesn't support javascript.
loading
A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation.
Llimos, Gerard; Gardeux, Vincent; Koch, Ute; Kribelbauer, Judith F; Hafner, Antonina; Alpern, Daniel; Pezoldt, Joern; Litovchenko, Maria; Russeil, Julie; Dainese, Riccardo; Moia, Riccardo; Mahmoud, Abdurraouf Mokhtar; Rossi, Davide; Gaidano, Gianluca; Plass, Christoph; Lutsik, Pavlo; Gerhauser, Clarissa; Waszak, Sebastian M; Boettiger, Alistair; Radtke, Freddy; Deplancke, Bart.
Afiliação
  • Llimos G; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Gardeux V; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Koch U; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Kribelbauer JF; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Hafner A; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Alpern D; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Pezoldt J; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Litovchenko M; Department of Developmental Biology, Stanford University, Stanford, CA, USA.
  • Russeil J; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Dainese R; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Moia R; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Mahmoud AM; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Rossi D; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Gaidano G; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Plass C; Cancer Research UK Lung Cancer Centre of Excellence, University College London (UCL) Cancer Institute, Cancer Genome Evolution Research Group, London, UK.
  • Lutsik P; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Gerhauser C; Institute of Bioengineering, School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Waszak SM; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Boettiger A; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Radtke F; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Deplancke B; Oncology Institute of Southern Switzerland, Università della Svizzera italiana, Bellinzona, Switzerland.
Nat Commun ; 13(1): 2042, 2022 04 19.
Article em En | MEDLINE | ID: mdl-35440565
ABSTRACT
Non-coding variants coordinate transcription factor (TF) binding and chromatin mark enrichment changes over regions spanning >100 kb. These molecularly coordinated regions are named "variable chromatin modules" (VCMs), providing a conceptual framework of how regulatory variation might shape complex traits. To better understand the molecular mechanisms underlying VCM formation, here, we mechanistically dissect a VCM-modulating noncoding variant that is associated with reduced chronic lymphocytic leukemia (CLL) predisposition and disease progression. This common, germline variant constitutes a 5-bp indel that controls the activity of an AXIN2 gene-linked VCM by creating a MEF2 binding site, which, upon binding, activates a super-enhancer-like regulatory element. This triggers a large change in TF binding activity and chromatin state at an enhancer cluster spanning >150 kb, coinciding with subtle, long-range chromatin compaction and robust AXIN2 up-regulation. Our results support a model in which the indel acts as an AXIN2 VCM-activating TF nucleation event, which modulates CLL pathology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article